Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.44 |
| ▸ | ITGAV | P06756 | 6/20 | 0.44 |
| ▸ | THRA | P10827 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23868241 | 0.69 | ITGB3 (0.54) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21100942 | 0.68 | ITGB3 (0.70) | ITGB3ITGAV | |
| SCHEMBL23153242 | 0.65 | ITGB3 (0.43) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL21479481 | 0.65 | ITGB3 (0.70) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL25955792 | 0.63 | THRB (0.44) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153245 | 0.63 | ITGB3 (0.42) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL19696737 | 0.62 | THRB (0.52) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153285 | 0.62 | ITGB3 (0.39) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL25819428 | 0.62 | THRA (0.42) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153267 | 0.62 | ITGB3 (0.42) | ITGB3ITGAVTHRATHRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885THRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.